Figures & data
Figure 1. Schematic representation of exposure measures used. The basic time-dependent design considers a patient exposed from the first prescription of glargine onward. Cumulative exposure measures were included as a refinement, where patients are stratified by (a) cumulative exposure to insulin glargine during follow-up, (b) duration of exposure to other insulin types before the start of glargine treatment, and (c) stratified to insulin-naïve starters of glargine and patients switched to glargine.
Table 1. Baseline characteristics of incident insulin users started on insulin glargine, non-glargine insulin, or both.
Table 2. Hazard ratios for breast cancer associated with the use of insulin glargine, stratified by cumulative duration of glargine use during follow-up and by cumulative exposure to other insulins before the initiation of glargine therapy.
Table 3. Hazard ratios for breast cancer associated with the use of insulin glargine, among insulin-naïve glargine users and glargine users with prior exposure to other insulins, stratified by categories of cumulative glargine use and adjusted for use of other insulins before the start of glargine.
